Lipid Matters

An exciting series of insights and discoveries in lipid science, brought to you by a diverse line-up of contributors! Dive into our blog for fresh takes on ground-breaking publications and thought-provoking items that push the boundaries of lipid research.

21st September 2026

Fmp30p Modulates CoQ biosynthesis via a PI-PLD

Just when you think our knowledge about phosphatidylinositol (PI) metabolism is getting to be near complete, a new study appears that highlights an unexpected finding. This is the case with a study from David Pagliarini’s lab at Washington University in St. Louis (Baker et. al Nat Commun. 2026 May 30;17:7013. doi: 10.1038/s41467-026-73766-x). This study used genetic, lipidomic, and other biochemical approaches and discovered that a metallo-β-lactamase in S. cerevisiae residing in the mitochondrial intermembrane-space, Fmp30, has PI-phospholipase-D activity.Importantly, they further show that this enzyme plays a critical role in regulating coenzyme Q (CoQ) biosynthesis.While a mammalian counterpart of Fmp30 has not been identified, the authors do show that there is a similar relationship between PI levels and CoQ levels in mammals. Overall, not only have their studies uncovered a previously unknown link between mitochondrial PI metabolism and CoQ production, their data also suggest this relationship could have new therapeutic potential for disorders involving CoQ deficiency.

Archive

2026

17 August 2026

Something New Regarding PLD1 Activation: PLD1 Activation by Arf11

PLD1 is a well-studied enzyme that hydrolyzes phohsphatidylcholine to produce free choline and phosphatidic acid. The enzyme has received considerable attention as the phosphosphatidic acid product is a second messenger, and the activity of this enzyme has been implicated in a number of pathologies. Previous studies have shown that PLD1 is activated by Rho- and ARF- GTPases .While it is known that Rho-GTPase bind at one well-defined specific site, ARF GTPases, such as the ARF-like GTPase 11 (ARL11), bind at a separate site which has not been clearly defined. In a recent study from the Airola lab (Marr et. all J Biol Chem. 2026 Jul 28:113375.Online ahead of print) show that ARL11 must be in a GTP-bound state to stimulate PLD1, and confirmed the requirement for the PLD1-specific loop to be in the catalytic domain for this activation. Using AlphaFold 3 structural predictions and mutational analysis, the authors further identify the likely ARL11–PLD1 interaction interface. Interestingly, they also found that the N- and C-terminal ends of PLD1’s disordered loop likely fold into secondary structures upon ARL11 binding, and that these structured elements are sufficient for stimulation even when most of the loop is removed. Overall, this study indicates that ARL11 activates PLD1 through three neighboring interaction surfaces, and, most intriguingly, that disorder-to-order transitions in PLD1 are involved in its regulation.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



3 August 2026

New ways of using MS to uncover critical protein-lipid interactions.

Lipids are essential biomolecules that play diverse roles across all aspects of biology. One essential function relates to modulating and supporting the activity of proteins that are either transmembrane, or membrane bound, including immune signalling complexes, coagulation factors, complement components, and many others. Where proteins directly rely on lipids for their function, the study of these proteins can be challenging since removing or damaging (e.g. using detergents) the membrane environment can change tertiary structure leading to loss of activity. While we know that specific lipids are essential for particular proteins, for example phosphatidylserine (PS) supporting coagulation factor binding to the surface of platelets, until recently, there were limited techniques available for defining lipid-protein interactions. Also, many of these relied on artificial in vitro systems. Beyond this, live cell-based approaches include a technically challenging method using bifunctional lipids (containing a photoactivatable group combined with “click” chemistry) and antibody-based pulldowns. While these approaches have greatly added to our understanding of lipid-protein interactions, neither are readily adaptable for systematic screening of proteins in general.

A recent technical report by Paquola et. al, from the Eggert lab at King’s College London has taken a new approach to this question, using a GFP tag to magnetically pull out proteins of interest and then apply high resolution MS to identify associated lipids (https://doi.org/10.1038/s41556-026-01928-6). The team focused on the process of division using HeLa cells and targeted a series of proteins well known to be involved. There are many questions that can be asked of this approach, including how do you know that a specific lipid is truly associated with the protein of interest and not just co-purifying with membrane fragments? Or, how do you know you’re not losing critical associated lipids through the washing process? Reassuringly, the method was validated using two proteins already known to interact with specific lipids, lactadherin, whose C2 domain binds PS, and TOM20, a mitochondrial protein which should be associated with cardiolipin. In both cases, lipids predicted to be associated were detected adding confidence that the method worked as expected.

The method was next applied to a series of proteins involved in cell division, including RACGAP1 and proteins of the ESCRT-III abscission machinery. Interestingly, the pattern of associated lipids differed when the cells were actively dividing suggesting that membrane dynamics of lipid-protein interactions were actively modulated during this process. The authors propose that varying the experimental conditions may lead to identification of tightly bound versus associated lipids, or even other locally bound proteins (if proteomics is applied to isolates). Other adaptations could include proteins tagged with various tags or the application of the method to cell free membrane biophysical studies. While this method is readily applicable to cells which can be genetically manipulated, there are caveats. One is that expression and localisation, as well as function of the studied protein needs to be the consistent with the endogenous protein. While the GFP tag allows fluorescence microscopy to confirm expression and localisation, it could itself lead to some changes in lipid-protein interactions, that wouldn’t be completely mitigated through a separate control GFP-protein target. A second caveat is that the method won’t be suitable for all primary cells or tissues since it relies on genetic overexpression of the target. Nonetheless, this elegant approach represents a powerful way to begin to interrogate families of proteins involved in critical biological processes and is likely to be widely adopted in the field.

Valerie O’Donnell

Cardiff University



20 July 2026

New Target for Treating Barth Syndrome: ABHD18

The remodeling of nascent cardiolipin (nCL) involves its diacylation to remove saturated fatty acids, followed by its reacylation with polyunsaturated fatty acids generating mature cardiolipin (CL). The diacylation is catalyzed by an enzyme known as ABHD18 (alpha-beta hydrolase domain 18) leading to monolysocardiolipin (MLCL) while the reacylation is catalyzed by an enzyme known as Tafazzin (TAZ). This remodeling is essential to establish the proper membrane curvature, and stabilization of proteins involved in the electron transport chain. Defects in this remodeling lead to metabolic defects, with Barth Syndrome receiving much of the attention. This syndrome is caused by a genetic mutation in the Tafazzin gene. Much of the past research into treatments of Barth Syndrome have focused on symptom management. I recently found a paper I had missed as it was published in September of 2025 by Masud et al. This paper suggests a potentially powerful approach to this disease may be to inhibit the ABHD18 deacylating enzyme. The authors show that preventing or reducing ABHD18 activity, even with small molecule inhibitors, compensates for TAZ deficiency. This may be a new and powerful approach to treating Barth Syndrome.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



6 July 2026

Mapping lipid cargo across the human lipid transfer proteome

A systematic map of which lipids are carried by which lipid transfer proteins (LTPs) was published earlier this year by Titeca et al.. The study analyzed hundreds of human LTPs for their lipid cargo and validated the hits functionally: if a transporter moves a specific lipid, overexpressing it should perturb the metabolic flux and steady-state equilibrium of that lipid, thereby measurably shifting the total cellular lipid composition. This closed-loop logic -screening, followed by functional perturbation via gain-of-function experiments, and finally measuring the resulting changes in the whole-cell lipidome - is what gives the dataset credibility beyond a simple binding catalogue.

With this large amount of data, the researchers were able to discover general rules about how LTPs transport lipids. Rather than acting as highly specific, single-cargo machines, most LTPs seem to interact with multiple lipid classes simultaneously. Beyond headgroup recognition, acyl chain properties often play a consistent role, particularly for glycerophospholipids, where LTPs frequently mobilize species with shorter fatty acids and one or two degrees of unsaturation, likely because these are easier to extract from membrane bilayers. However, this may not be a universal rule.

These nuanced binding preferences are key to understanding the LTP network as a whole. The dataset provides a systematic characterization of LTP-lipid complexes, revealing functional relevance for both known and newly identified ligands. How cells orchestrate directional lipid flow across dozens of transporters simultaneously is a question the field can now begin to ask in a much more systematic way, and this resource provides a solid foundation to do so.

Olya Vvedenskaya, MD, PhD

Lipotype



22 June 2026

Eigenlipids

This blog will be a bit different from most. Why? Because a colleague of mine recently sent me a review (Sing et al. J Lipid Res. 2026, online ahead of print) of an approach in lipidomic analyses that I must admit I hadn’t heard of: Eigenlipids. The approach is derived from an approach first used and popularized in transcriptomics. Eigenlipids may turn out to be an important tool for the analyses of lipids observed in lipidomic studies but there are, however, some drawbacks. Eignelipids derive their name from eigenvectors and eigen values and represent clusters of lipids, termed modules. In general, highly correlated lipids are separated into clusters or "modules". Each module is subjected to principal component analyses (PCA) and the resulting principal components are ordered according to the fraction of a total variance, and the first principal component is designated as the "eigenlipid" for that entire module of lipids. The review, introduces eigenlipids, their construction and use to examine lipid metabolism in biological systems. It also highlights current limitations and presents new potential strategies for eigenlipid generation. It’s not clear how useful this will actually be in a final analysis, but it is something that will likely be discussed further in the near future.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



8 June 2026

Evidence for a new phospholipid class generated in bacteria from condensation of PI and PA.

The discovery of lipid molecular species continues to be a hot topic, with huge interest in microbial lipidomes leading to regular identification of new compounds from across the range of LIPID MAPS lipid categories. Relating to this, a paper from Abreu et al. claiming to identify a new category of phospholipids, based on condensation of two well-known PLs (PI and PA) was published recently in the Journal of Natural Products. It’s interesting to review this as it provides an opportunity for us to consider…what evidence do we need to be able to claim a new structure, and if we don’t have enough, how do we ensure that we communicate the right level of caution to readers?

Even if the structure is not fully elucidated, providing the evidence with a description of a “proposed” structure, and including statements about what additional evidence would be required is important, since this will stimulate others to follow and refine the structure as needed. But what we always need to be careful of is not overclaiming, e.g. not claiming structural features such as stereochemistry or functional group position where it’s not proven.

In this study, a new class called PIPA (phosphatidylinositol–phosphatidic acid) were proposed to be present in Streptomyces strains, with the evidence being obtained from normal phase chromatography coupled to high resolution mass spectrometry. The first pitfall that researchers can fall into relates to not using chromatography to separate lipids, where in source adducts form that masquerade as actual molecular species…. This issue doesn’t apply to this paper, where NPLC was used, and it was shown that the lipids elute between cardiolipin and PI. This confirms they are discrete molecular species. They elute far later than glycerides but right in the middle of the PL categories as expected for the proposed structures. Another question is whether they could form chemically during lipid extraction, e.g. if non-standard or harsh conditions were used. In this study the process was a straightforward Bligh and Dyer extraction, making this unlikely.

The MS data presented shows a large cluster of molecular species in negative ion mode from around m/z 1397-1453. One of these lipids, proposed as 15:0_16:0 containing PI and PA condensed at the phosphates was selected for MS2 and MS3, and data broadly agrees with the fragmentation proposed, namely: loss of DG 16:0_15:0, a headgroup ion consisting of inositol and 2 phosphates, and several other ions consistent with FA losses or the FA carboxylate ions for 15:0 or 16:0. The presence of inositol was suggested based on lack of reactivity of the lipid with compounds that would indicate hexoses instead. However, lack of evidence isn’t quite the same as evidence, and a second issue with the study is the complete lack of any synthetic standards with which to confirm retention times or fragmentation patterns. As with all of these types of studies, when dealing with complex biological mixtures, purification of material for NMR was presumably not feasible.

How confident can we be of this new PL category? The authors state that while the chemical structure suggests a condensation between PI and PA, it doesn’t allow any conclusion to be drawn regarding biosynthesis. While this is true, it was also stated in the paper that “a detailed methodological framework is presented in this study, allowing for the characterization of different lipid classes and the discovery of a novel class of lipids called PIPA.” The question to ask is…is MS data in the absence of a synthetic standard or NMR, evidence enough to claim a structure? History tells us to be cautious and that this should be evidence to propose a structure, but we should be clear that further evidence, such as direct comparison with a standard is required to substantiate this assertion. It will be interesting to see further work on this new and interesting PL class as it emerges.

Valerie O’Donnell

Cardiff University



26 May 2026

A Chloride Channel-like Protein Assists in Lipoprotein Biogenesis and Nuclear Pore Formation

I’m often surprised when I see evidence for a protein-protein interaction that I would have never suspected. Such is the case for two recent papers that described the interaction of endoplasmic reticulum-localized anion channel, CLCCL1 (chloride channel CLIC-like1), and a lipid scramblase TMEM41b.Using cryo-electron tomography (cryo-ET) coupled with high-pressure cryo-fixation (HPF), the Wu lab showed that association of CLCC1 with the TMEM41b is required for normal formation of lipid droplets (Nature 652, pages471–480 (2026)). The notion is that CLCC1 assists in modulating the trans-bilayer equilibration of phospholipids. It’s interaction with TMEM41B promotes lipid scrambling leading to lipoprotein biogenesis. A companion paper from the Olzmann lab (Nature 652, 462–470 (2026)) takes a more genetic approach involving CRISPR-Cas9 screens and notes that CLCC1 is structurally similar to yeast Br1 and Br6 proteins involved in NPC formation. They provide evidence that the loss of CLCC1 also reduces the number of nuclear pores. Taken together, these studies show the importance of the interaction of both CLCC 1 with TMEM41b in both lipoprotein and nuclear pore biogenesis.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



8 May 2026

A new role for ATG2A: moving neutral lipids, not just phospholipids.

Bridge-like lipid transfer proteins (BLTPs) have long been known to facilitate bulk movement of phospholipids across membrane contact sites. Through this, they allow trafficking of lipids between different bilayer membranes, for example during autophagy when source membrane lipids are directed to autophagosome precursor membranes.

In contrast, up to now, processes that support movement of neutral lipids between organelles have not been identified, for example triglycerides (TGs) contained in lipid droplets (LDs). Here a key difference is that the membrane is a monolayer, not a bilayer, and so the microenvironment will be very different to that of all other cell membranes. Highlighting this, transmembrane proteins can’t bind/insert into the surface of LDs.

Addressing this question, a recent paper in Proceedings of the National Academy of Sciences has demonstrated that the BLTP member, ATG2A, well known for its roles in driving autophagy (where it moves lipids from the ER to the phagophore), may have a far wider role in lipid metabolism. Just to give some context to this protein and its importance, the roles of ATG2 (A and B) in autophagy were identified in the lab of Yoshinori Ohsumi and colleagues in Tokyo and contributed directly to the awarding of the Nobel Prize in Medicine or Physiology in 2016 for discovery of molecular processes of autophagy.

In this new study, Korfhage et al found that ATG2A, which is known to be associated with LD, can also transport TGs between organelles.This indicates it also acts as a neutral lipid transfer protein. In some ways, it wasn’t entirely surprising considering that it’s long been known to be located on LDs, however that it can also work on lipid monolayers considering the biophysical constraints is intriguing.

Here, using synthetic membrane systems and lipidomics of purified ATG2A, the team showed that the protein binds especially well to LD monolayers, where it transfers lipids efficiently. Surprisingly, TG movement had similar kinetics to phospholipid transport, indicating ATG2A can traffic both structural membrane lipids as well as those involved in energy storage.

Why does this matter? LDs are increasingly recognized as being multifunctional dynamic organelles that play essential roles in diverse functions including energy balance, membrane homeostasis, and inflammatory/stress responses. This new study suggests ATG2A may also support lipid exchange between LDs and other organelles, linking autophagy with many other functions. Through this, it suggests a potential involvement of BLTPs as regulators of whole-cell lipid biochemistry.

Intriguingly, such a widening of the functions of BLTPs suggests a far broader functions in maintaining human health and disease. So far, mutations in ATG2A (or B) are not known in human disease, suggesting that they may be embryonically lethal. A few reports link ATG2 variants to disease phenotype but this is not widely studied or validated as yet. If ATG2A is a TG transfer protein, we may expect to see an impact on hepatic steatosis, atherosclerosis, brown fat thermogenesis, lipotoxicity and other metabolic conditions but that’s for future study.

Open access version is here

Disclaimer: ChatGPT kindly helped with research on this topic, and summarizing of the article, but all facts were checked.

Valerie O’Donnell, Cardiff University



14 April 2026

Another Role for PtdIns(3,5)P2:In Immune Signaling

Foreign, or even misplaced DNA, in the cytosol trigger innate immune signaling that involves the induction of Type I interferon and proinflammatory cytokines. This is important as it participates in the defense of pathogens and clearance of damaged cells. A major pathway implicated in this response is termed the cGAS-STING (cyclic GMP–AMP synthase–stimulator of interferon genes).While this is a well-studied system, a new report by Tan et al. provides intriguing evidence for a PtdIns(3,5)P2 role in this signaling system. Specifically, the authors show that PtdIns(3,5)P2 binds directly to STING and promotes cGAMP-induced oligomerization. Depletion or mutation of PIKFYVE, the enzyme responsible for producing PtdIns(3,5)P2 in mammalian cells, or mutation of the PtdIns(3,5)P2-binding residues in STING suppresses its signaling. These findings reveal another role for PtdIns(3,5)P2 in innate immunity.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



31 March 2026

Opening the window to unusual PL and how they are made.

When it comes to phospholipids (PL), the most abundant species are asymmetric, with generally a saturated fatty acid (FA) attached at sn-1, and an unsaturated (e.g. PUFA) at sn-2. As lipidomics technologies have advanced in recent years, methods such as ion mobility spectrometry (IMS) and enhanced fragmentation (e.g. ozone-induced dissociation) have allowed profiling of the exact positions of individual FA in PL. These revealed that species that don’t follow this rule exist as minor components, where a PUFA is instead found at sn-1. Very little is known about these “atypical” PL, for example how they are made, and also, why. Whether they have functions independent of the more abundant species is totally unknown. The formation of asymmetric PL is considered to be determined by Lands’ cycle remodelling, the process by which saturated FA-containing PL are hydrolyzed, then reacylated by lysophospholipid acyltransferases (LPLATs) working in concert with fatty acyl-CoA synthetases (ACSLs). Lands’ cycle was originally discovered in the 1950’s and is still considered the key process generating classic tissue PL signatures through remodelling largely saturated PL species to asymmetric that contain PUFA at sn-2. But what about sn-1?

LPLATs exist as 14 separate proteins, with varying substrate specificities, some preferring longer chain FA or arachidonate (AA) while others are involved in generation of phosphatidyl acid (PA) rather than PL. Most of what is known concerns remodelling at sn-2, while the remodelling at sn-1 is less characterized. One reason for this has been technical.LysoPL with the FA at sn-2 are not stable, with rapid migration of the FA to sn-1 happening under physiological conditions. In this study, being able to prevent acyl migration using acidic conditions has enabled Kawana et al in a recent study published in the Journal of Lipid Research to begin to study the process of sn-1 remodelling through the preparation of large amounts of lysoPL substrate with the FA at sn-2 instead. Using this and LPLAT knockout mice, they were able to identify that the isoform Lplat10 (in mice) was responsible for acylation of unsaturated FA including oleic, linoleic, AA and DHA into sn-1 of LPC, LPE and LPS as acyl acceptors but not LPI, LPG or LPA. LPLAT10 was highly expressed in neurons, while brain tissue lacking it showed significantly different PL composition, consistent with its proposed role in remodelling.

This study stands out for various reasons. New generation profiling methods such as IMS and enhanced fragmentation have become increasingly popular with many researchers using them to find new lipids. While generally these are less abundant, this doesn’t make them less interesting. In fact, history tells us that low abundance lipids can often be extremely important, for example through mediating receptor-dependent signaling processes. Moving beyond the discovery of these unusual PL species, Kawana et al started to unravel the underpinning biochemistry. The fact that these PL come from a biosynthetic pathway that is regulated and tissue specific suggests a defined biological role. Although mice lacking LPLAT10 did not show any obvious defects, how they respond to disease challenge has not yet been tested. Future studies on these mice may help reveal why mammals make these unusual lipids and whether this links to human disease.

Valerie O’Donnell

Cardiff University



31 March 2026

Structures of a lipin/Pah phosphatidic acid phosphatase

The conversion of phosphatidic acid (PtdOH) to diacylglycerol is important for triacylglycerol synthesis as well serving to convert one signaling molecule (PtdOH) into another (DAG). Lin/Pah phosphatidic acid phosphatases (PAPs) are important Mg+2-dependent enzymes that catalyze this conversion. Indeed, deficiencies in PAP activity has been associated with inflammatory disorders in humans. Despite the importance of these enzymes, there has been interest in understanding their structure and regulation. In December of 2025, the Airola lab published high resolution (1.95–2.40 Å) structures of a PAP in Tetrahymena thermophila Pah2. Their data resolve active and inactive states involved in catalysis. In addition to the active and inactive states, the data highlight the role of two highly conserved aspartate and arginine residues in coordinating with Mg+2 and are involved in the recognition of PtdOH. The data provide some new and critical structural insights involved in catalysis and defines an important Asp-Arg motif in lipin/Pah PAPs. These data will certainly lead to more mechanistic insight into the catalytic chemistry of these enzymes.

Valerie O’Donnell,

Cardiff University



16 March 2026

Prescription Medicines and Cholesterol Biosynthesis

Cholesterol is an essential structural molecule, it is a regulator of its own synthesis via convergent inhibition, and a precursor a myriad of signalling molecules. Cholesterol is particularly important in the CNS which contains about one quarter of the cholesterol found in the whole body. In all mammals, the majority of growth and differentiation of the CNS occurs during the late stages of embryonic development and early after birth, when all cholesterol in the CNS comes from de novo synthesis. Inherited metabolic deficiencies in enzymes of post-lanosterol cholesterol biosynthesis, such as in 7-dehydrocholesterol reductase (DHCR7), which leads to Smith-Lemli-Opitz syndrome (SLOS), are often characterised by complex neurodevelopmental problems and dysmorphologies and this has led to an increased interest in prescription medicines which inhibit DHCR7, particularly during pregnancy.

The effects of prescription medicines on enzymes of post-lanosterol pathways were reported by Hall et al in 2013 who found, by examining medical histories, that aripiprazole, an antipsychotic medication, and trazodone, an antidepressant, resulted in elevated concentrations of 7-dehydrocholesterol (7-DHC). These medications were later shown to inhibit DHCR7 explaining the elevation of 7-DHC. More recent work by Korade, Porter and colleagues has found evidence for more than 30 medications disrupting post-lanosterol sterol biosynthesis. Of these, Tallman et al now report in detail on how 11 selected medications disrupt cholesterol biosynthesis pathways. Each medication was tested on human dermal fibroblasts and 13 post-lanosterol metabolites measured by quantitative LC-MS/MS. By measuring substrates and products of the enzymes in the pathways the exact effect of each medication on the pathways was evaluated. Many of the medications were shown to inhibit DHCR7 including cariprazine, an antipsychotic, nebivolol, an antihypertensive, and rotigotine, used in the treatment of Parkinson’s disease, depression and restless leg syndrome, importantly, the concentrations of 7-DHC approached levels seen in SLOS fibroblasts. Other medications had duel effects on enzymes of the pathways. Buspirone, an antidepressant, and lurasidone, an antipsychotic, inhibit DHCR7 and dehydrocholesterol reductase 14 (DHCR14); amiodarone, used to treat irregular heartbeats, inhibits both desmosterol reductase (DHCR24), inherited deficiency of which leads to desmosterolosis, a disorder which like SLOS presents with dysmorphology, and 3β-hydroxysteroid-Delta(8),Delta(7)-isomerase, genetic deficiency of which leads to MEND (Male EBP disorder with neurologic defects) and CDPX2 (X-linked dominant chondrodysplasia punctata-2); while vilazodone, used to treat depression, and ziprasidone, an antipsychotic, both inhibit DHCR7, DHCR14 and DHCR24.

The significance of this study by Tallman et al is that many of these medications are routinely prescribed to pregnant women and sterol biosynthesis is critical during intrauterine and early postnatal life. This is an important area of future research as exact mechanisms of sterol inhibition have yet to be uncovered and the ultimate effects on human health will be dose dependent and the problem of polypharmacy still needs to be considered.

Yuqin Wang and William Griffiths

Swansea University



12 March 2026

Beef lipidomics and health implications

A 2025 lipidomic analysis by Elliott and colleagues characterized the distinct lipid profiles of lean muscle (LM), intramuscular fat (IMF), and subcutaneous fat (SF) in beef strip loin (Elliot, 2025) using shotgun lipidomics. The resulting mass spectra were analyzed to identify and provide absolute quantification for 882 distinct lipid species across the different tissue types. The study confirmed that each tissue contributes a unique lipidome. Fat depots (IMF and SF) were composed almost entirely of storage lipids (>96%), primarily triacylglycerols (TAGs), whereas lean muscle was markedly enriched in structural lipids - phospholipids and sphingolipids accounted for more than 30% of its total lipid content.

It is important to underline that the authors do not address sensory attributes such as taste, flavor, or palatability. Their objective was strictly biochemical: to generate a quantitative lipidomic characterization of lean muscle, intramuscular fat, and subcutaneous fat, and to clarify how each contributes to the broader ‘beef matrix’.

These compositional differences have methodological implications. If LM, IMF, and SF each carry distinct lipid classes and proportions, then ‘red meat’ is not a uniform type of food. The specific balance of lean and fat tissue becomes a critical variable that should be accounted for in nutritional epidemiology. Many existing studies on red meat consumption and health outcomes overlook this nuance and fail to specify the type of meat consumed or its degree of marbling.

Clinical studies further illustrate why this distinction matters. For example, lean red meat, when trimmed of visible fat and consumed within a diet low in saturated fatty acids, does not adversely affect plasma LDL cholesterol (Li, 2005). This clinical pattern is metabolically consistent with the observation that lean muscle is enriched in structural lipids rather than storage TAGs (Elliot, 2025).

Failing to differentiate lipid compositions in beef (and other red meat) introduces a substantial confounding variable that can negatively affect the analysis of the relationship between meat consumption and health outcomes. The conclusions from Elliot et al., therefore, argue that future research should stratify analyses by the type and composition of beef products to ensure greater accuracy and interpretability.

In summary, the health implications of red meat consumption are complex and depend on meat processing, the specific lipid composition of the cut, and the broader dietary matrix in which it is consumed.

Olya Vvedenskaya, MD, PhD

Lipotype



24 February 2026

A Lysolipid for Treating Obesity?

After the recent holidays, thoughts of overeating and obesity occupy an increased amount of space in our minds. Given this, and the interest of the readers of this blog, I thought it would be interesting to bring some attention to a recent article suggesting a mechanism by which obesity may be combated by using lysophospholipid, 1-linoleoylglycerophosphocholine (1-LGPC). This mechanism capitalizes on a new potential connection between 1-LGPC and the KEAP1-Nrfs (Kelch-like ECH-associated protein 1 - Nuclear Factor Erythroid 2-Related Factor 2) axis. This axis is a recognized cellular system that defend against oxidative and electrophilic stress. In this axis, KEAP1 binds NRF2 and tags it for degradation, and when stress signals are present (e.g. ROSs), KEAP1 releases NRF2 upon which it to enters the nucleus, bind to DNA, and activate protective genes such as antioxidant enzymes (e.g. HMOX1), detoxification enzymes (e.g. GSTs), as well as metabolic enzymes and enzymes involved in autophagy. In a recent article by Wang et al , the authors report a decline in 1-LGPC in the blood of obese patients. Interestingly, 1-LGPC reduced the high-fat diet-induced lipid accumulation in zebrafish larvae and in human adipocytes. Their data indicated that uncoupling protein 1-dependent thermogenesis and mitochondrial respiration were significantly boosted. Importantly, NRF2 expression and nuclear translocation were induced by 1-LGPC. Other data indicated the KEAP1-Nrf2 axis was involved in the 1-LGPC-induced energy expenditure. The authors suggest their results provide a new and interesting insight into a novel physiological role for 1-LGPC in obesity and points to a new target for treating obesity. I should note that there could approaches to confirm and strengthen their conclusions such as the use of another lysolipid, and an alternative to using brusatol such as an RNAi knockdown Nrf2. Nonetheless, their results are indeed intriguing.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



3 February 2026

Pseudo-Leukotrienes: bioactive lipids generated through autoxidation during inflammation.

Lipid oxidation is catalyzed either by enzymes, or mediated by unregulated chemical processes involving redox active iron and/or highly reactive free radicals. For the latter, a complex back and forth of initiation, propagation and termination reactions results in a massive expansion of products formed. While tightly-regulated enzymatic oxidation generates bioactive lipids that play essential roles in physiology, non-enzymatic oxidation is generally considered toxic and a major contributor to tissue damage in both acute and chronic disease.

Despite their biosynthetic differences, there are major overlaps between these two processes driven by the structural similarities of the resulting products made. For example, it has been long known that non-enzymatically generated isoprostanes can act in similar ways to their cyclooxygenase-derived prostaglandin isomers, although generally this is with less potency and specificity.

Recently, extending our knowledge of the cross over between enzymatic and non-enzymatic oxidation, Robert Salomon’s group from Case Western University, Cleveland, identified a new family of radical-induced lipid oxidation products that they termed pseudo-leukotrienes (øLTs). These are proposed to be generated through AA oxidation (while AA is still in the phospholipid pool), followed by its truncation and PLA2 cleavage to form HOOA (5-hydroxy-8-oxo-octanoic acid), which is followed by Michael addition of glutathione to form DHOA-GSH. Peptidase activity is then proposed to sequentially remove amino acids from the GSH to generate further metabolites, with the lipids given names reflecting their structural similarity to leukotrienes, øLTC, øLTD, øLTE and N-Ac-øLTE. Here, there are assumed to be 4 diastereomers due to the free radical processes involved. In a first paper, total synthesis approaches were used to generate internal and primary standards. These were then used to quantify the lipids in both this and a more recent paper , in biological samples that included retinal pigment epithelial cells, urine from asthma patients, and mouse lung following allergen exposure. Levels of the lipids were significantly higher in severe asthma (urine), and correlated with severity, and were also increased in BAL from mice with after allergen exposure. Last, it was shown that øLTs could induce signaling in cultured cells that was mediated via CysLTR, although with somewhat lower potency. Interestingly, the urine concentrations of these new molecules was far higher than those of CysLTs.

A major strength of the paper is the use of synthetic standards to confirm structure, and in the first paper, co-elution of øLTC in mouse lung homogenates with both the synthetic and labelled (3C215N) internal standards provided strong evidence, although a limitation is that only one MRM channel was followed and corresponding data for the other lipids weren’t shown. It can be challenging to obtain clean MS/MS spectra of (low abundance) endogenous lipids in complex tissues, so another approach, recently outlined in a community guideline for oxylipin analysis is to monitor secondary (or even tertiary) MRMs, which can then confirm that fragments of interest co-elute on LC with the lipid of interest and have the same ion ratios. It may also be interesting to run the biological extracts on a chiral column to determine the prevalence of the stereoisomers expected to also be present in these mixtures (to confirm their non-enzymatic origin in biological samples). For interested readers, all four of the lipids have now been added to LMSD (for øLTB, and replace the 2 with 3,4,5 to see the rest).

Relating to nomenclature, while the name pseudo-LTs is used here to denote GSH addition and its subsequent metabolism, as well as their ability to activate CysLTR, it’s noted that it this name formally refers to lipids with a triene structure, which isn’t present here. Perhaps a name that more accurately reflects the full structures of these molecules could be considered, so as to avoid potential confusion on this point.

Discovery of new lipids that signal in inflammation is a vibrant field and no doubt, there are many more lipids remaining to be uncovered that originate either from enzymatic or non-enzymatic oxidation of PUFA. Further studies will establish whether monitoring urinary levels of these new and unique lipids will be useful for monitoring asthma severity or guiding treatment choice, as outlined in the recent study.

Valerie O’Donnell,

Cardiff University



19 January 2026

Mechanistic snapshots of lipid-linked sugar transfer

I’m always drawn to articles that highlight the need for structural studies that AI approaches can’t resolve. That’s why I was drawn to a recent article in Nature Communications by Morgan et al titled “Mechanistic Snapshots of Lipid-linked Sugar Transfer". The authors used UV-photolysis of a chemically caged substrate with cryogenic time-resolved electron microscopy (cryo-TREM) to examine the catalytic mechanism of a membrane-bound glycosyltransferase, GtrB. They were able to visualize conformational changes during the catalytic cycle that moves each substrate, UDP-glucose and undecaprenyl phosphate, in proximity for catalysis. They were able to visualize the initial substrate-bound state, a catalytically poised intermediate, and the product-bound state involved in catalysis.They further supplemented their results with molecular dynamics simulations and biochemical analyses, to identify the conformations within the active site that drive catalysis. This in an intriguing studies that represents the power of structural biology approaches that provide an understanding of a catalytic that would be very difficult if not impossible to obtain with AI approaches alone. Structural biology is still alive and well.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA



6 January 2026

The elusive origin of brain DHA, and the importance of publishing replication studies.


Supplementation with omega3 fatty acids derived from fish oil has been promoted as a neutraceutical approach towards maintaining health for at least 50 years now, driven in the early days by epidemiological data on diverse inflammatory conditions including cardiovascular disease and latterly, by studies on dementia risk. Of course, epidemiology does not prove cause and effect and in more recent times, several randomized clinical trials have conclusively failed to evidence the attractive idea that these lipids might be a panacea for any chronic diseases of ageing. One major question in this field relates to the bioavailability of omega3 fatty acids when orally administered. Dogma has been that dietary forms should be absorbed then taken up into cell membranes, particularly in the brain, where they’ll magically (through largely unknown but oft debated mechanisms) prevent cognitive decline. But does this idea hold up?

At the recent Society of Chemistry in Industry meeting in London on Lipids in Diet and Health, there was lively discussion of this exact question, initiated by a presentation from Richard Bazinet on his recent study in J Lipid Res. This seminal paper discussed how the brain is unable to make its own DHA, so it relies on other sources to maintain the high levels required for normal brain function. Here, Klievik et al set out to re-evaluate a series of studies by Sugasini et al, where supplementation with either LPC-DHA or di-DHA-PC was claimed to increase brain DHA content by up to 2-3 fold in mice. This was prompted by a recent study showing in contrast, that LPC-DHA supplementation didn’t increase brain DHA levels in Apoe3 and Apoe4 knock-in mice, and because as the authors state, they “are not aware of any direct evidence supporting the intact absorption of sn-1 DHA into the plasma”. In summary, in the recent study from Bazinet and colleagues, while oral supplementation of DHA either as PC or LPC led to significant enrichment in plasma and heart lipid pools, brain DHA levels were completely unchanged. This agrees with more recent data on this question cited by Bazinet, supporting the notion that the brain self-regulates its DHA levels rather than being influenced solely by what happens in the diet.

The importance of this study is twofold. First, it’s essential to understand where the brain derives DHA from, and how this could be regulated therapeutically. This study shows that in mice this is not from diet, leaving endogenous synthesis as the source. Indeed, in his seminal lecture at the SCI meeting, Richard presented new data beyond the published study, using natural abundance carbon isotope ratio analysis to demonstrate that DHA in the brain originates from endogenous synthesis. An earlier JLR paper describes this method.

The second reason that this paper is important is that it’s a replication study, performed in response to conflicting literature on the topic. Science depends on careful replication of key findings and all too often this doesn’t happen at all, or if it does, it occurs many years later having followed a long period of wasted time, funding and lost careers. Publication of negative data is difficult and hard work for all involved but it’s an essential part of science if we are to ensure the record is accurate. The field of omega3 fatty acids isn’t unique in facing this issue, nor are the issues addressed in this study by any means the only question marks hanging over fish oil neutraceutical claims. The editors of JLR should also be commended for supporting publication of replication studies, upholding standards in research through providing opportunities to correct and debate research respectfully through the process of peer review.

Valerie O'Donnell

Cardiff University



2025
2024
2023

Go to older Lipid Matters posts Bill Christie's occasional series of notes on publications or other items dealing with lipid science. For the previous curated collection of comments from the world of lipid research please visit - Lipid Trends